Concentration of RANKL, OPG, and TRAIL in the media collected from osteoclastic cultures of patients with MM with osteolysis (MM) and controls (Ctr)
. | Ctr . | MM- T cells . | MM+ T cells . |
|---|---|---|---|
| RANKL, pmol/L | ND | 0.3 ± 0.1 | 5.5 ± 0.5* |
| OPG, pmol/L | ND | ND | 2.5 ± 0.1* |
| TRAIL, pmol/L | 21 ± 0.9 | 21.54 ± 1 | 42.86 ± 0.57* |
. | Ctr . | MM- T cells . | MM+ T cells . |
|---|---|---|---|
| RANKL, pmol/L | ND | 0.3 ± 0.1 | 5.5 ± 0.5* |
| OPG, pmol/L | ND | ND | 2.5 ± 0.1* |
| TRAIL, pmol/L | 21 ± 0.9 | 21.54 ± 1 | 42.86 ± 0.57* |
RANKL indicates receptor activator of nuclear factor κB; OPG, osteoprotegerin; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ND not detectable; absence (-) and presence (+) of T cells in cultures.
P < .001 versus Ctr